Microspheres Approved for Tumor Embolotherapy

IMBiotechnologies Ltd. of Edmonton, Alberta has received 510(k) clearance from the FDA to bring their novel embolotherapy product to market in the USA. The Occlusin 500 Artificial Embolization Device (OCL 500) is a microspherical embolization agent approved for the treatment of highly vascularized, unresectable tumors, e.g., hepatocellular carcinoma or renal cell carcinoma. After being injected into a vessel supplying the tumor, the microspheres form a platelet-rich clot interrupting its blood supply. One advantage of the biodegradable agent is that the microspheres degrade over time, allowing the vessel to re-canalize, thereby maintaining the option of using the same vessel in the future for further treatments.
Product page: Occlusin 500…
Press release: IMBiotechnologies Receives FDA Clearance to Market Occlusin® 500 Biodegradable Microspheres in the U.S…